BOD Australia Limited (ASX: BDA, ‘Bod Australia’) released their quarterly activities and cashflow report for Q2 FY2019/2020.
What are the highlights?
BOD Australia confirmed sales for Q2 FY 2019/2020 of $536,000, which is slightly higher than Q1 FY2019/20 which stood at $507,000. $832,799 in binding purchase orders have also been received and will be invoiced and delivered in the March 2020 quarter. Furthermore, 1,842 MediCabilis™ prescriptions were made during H1 FY 2019/2020 with 799 prescriptions in Q2 FY 2020. MediCabilis™ is now being prescribed to treat 17 different conditions.
BOD Austraila are expecting:
- The introduction of new products and brands in collaboration with H&H in Australia and internationally;
- Further growth in MediCabilis™ prescription sales domestically and internationally;
- The pursuit of collaborations with key research groups to advance research into specific application for CBD, based on the use of MediCabilis™; and,
- The supply of MediCabilis™ products for trial stock for different medical conditions.